Streetbeat News

Regulatory

AMLX

Amylyx Pharmaceuticals has announced the publication of a survival analysis comparing the long-term survival of participants in the CENTAUR study versus a historical clinical trial control group. The results of this study could have significant implications for the company's future drug development and approval processes.

Portfolio Pulse from Bill Haddad

October 10, 2023 | 1:16 pm

BTCUSD

Ryan Selkis, CEO of Messari, a crypto market intelligence provider, celebrated a decade in the cryptocurrency industry by revealing his purchase of 10 Bitcoin (BTC) in 2013 for $135 per unit. With the current trading price of Bitcoin at $27,655.48 per unit, his initial investment would have increased by over 20,000%. Amid regulatory actions targeting major cryptocurrency exchanges, Selkis announced the establishment of a new advocacy group, @DFA2024, to combat fear, uncertainty, and doubt in the crypto sector.

Portfolio Pulse from Mehab Qureshi

October 10, 2023 | 1:13 pm

BFRI

Biofrontera Inc. has received FDA approval for a new formulation of its product, Ameluz.

Portfolio Pulse from Bill Haddad

October 10, 2023 | 1:06 pm

SPY

The USA Redbook Year-over-Year (YoY) has increased to 4% from the previous 3.5%.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 12:57 pm

CBWTF

Italy's Lazio Regional Court has suspended a decree prohibiting the sale of cannabinoid-based products for oral use or ingestion. In Canada, the cannabis 'strategy table' has selected Hugo Alves, CEO of Auxly Cannabis Group (OTCQB:CBWTF), as its chair. The group aims to improve the government's understanding of the cannabis sector's economic situation. In Australia, medical marijuana approvals have increased by over 120% in H1 2023 compared to the same period in 2022. A draft bill in Tasmania proposes the destruction of crops exceeding the 1.0% THC limit.

Portfolio Pulse from Nina Zdinjak

October 10, 2023 | 12:54 pm

ABBV

AbbVie (NYSE:ABBV) will present new data from its gastroenterology portfolio at the United European Gastroenterology (UEG) Week 2023 Congress. The data includes late-breaking results from a study comparing SKYRIZI (risankizumab) and STELARA (ustekinumab) in treating moderate to severe Crohn's disease, and analyses from AbbVie's maintenance trials for SKYRIZI and RINVOQ (upadacitinib) in treating Crohn's disease and ulcerative colitis. The company will also present primary efficacy and safety results from the Phase 3 INSPIRE induction study for risankizumab in ulcerative colitis.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 12:49 pm

EEIQ

EpicQuest Education Group International Limited (EEIQ) announced an operations update for Davis College, highlighting progress in international recruitment, collaborative programming, and regulatory approvals. The college has seen a three-fold increase in international student enrollment for the current academic quarter compared to the year-ago period. Davis College has also entered into agreements with Beijing New Oriental Vision Overseas Consulting Co., Ltd. for recruitment and Peking University for a two-year continuing education and training program. The Higher Learning Commission has approved Davis College for all of its education courses and programs offered online.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 12:48 pm

AYRO

AYRO, Inc., a designer and manufacturer of electric delivery vehicles, has been issued a U.S. Patent for technologies associated with vehicle environmental impact reduction and elimination. The patent, titled 'Systems and Methods for Controlling Vehicle Acceleration to Regulate Environmental Impact,' describes a vehicle designed to adjust its impact on the ground it traverses. The company has also been honored with two prominent awards in 2023 and has secured multiple design patents and utility patents for the AYRO Vanish.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 12:47 pm

PBTS

Powerbridge Technologies Co., Ltd. (NASDAQ:PBTS) has regained compliance with the Nasdaq minimum bid price requirement. The company's ordinary shares have been at $1.00 per share or greater for 10 consecutive trading days, from September 22 to October 5, 2023. Previously, the company was not in compliance with the minimum bid price requirement for 30 consecutive business days from June 28, 2023 to August 10, 2023.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 12:41 pm

INZY

Inozyme Pharma, Inc. (NASDAQ:INZY) has highlighted the inclusion of Generalized Arterial Calcification of Infancy (GACI) in the Genomics England's Generation Study. This research initiative, developed to advance early detection and treatment of rare genetic conditions, is set to begin in late 2023. Inozyme is developing INZ-701, an enzyme replacement therapy, for the treatment of rare disorders like GACI.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 12:35 pm